FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although several prior clinical trials testing SRC or COX2 inhibitors in patients with CRC have failed to show meaningful clinical activity48–53”
From A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors (2023) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
Research works printed but not linked: 18
- Douillard, 2000, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial, Lancet, 355, 1041, 10.1016/S0140-6736(00)02034-1 · DOI · Paper page
- De Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938 · DOI · Paper page
- Colucci, 2005, Phase III randomized trial of FOLFIRI vs FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico dell’Italia Meridionale (GOIM), J Clin Oncol, 23, 4866, 10.1200/JCO.2005.07.113 · DOI · Paper page
- Dannenberg, 2001, Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer, Lancet Oncol, 2, 544, 10.1016/S1470-2045(01)00488-0 · DOI · Paper page
- Yamauchi, 2002, Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer, Dis Colon Rectum, 45, 98, 10.1007/s10350-004-6120-5 · DOI
- Gupta, 2001, Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2, Nat Rew Cancer, 1, 11, 10.1038/35094017 · DOI · Paper page
- Arber, 1999, Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer, Curr Gastroenteral Rep, 1, 441, 10.1007/s11894-999-0027-1 · DOI
- Church, 2003, Cyclo-oxygenase 2 inhibition in colorectal cancer therapy, Br J Surg, 90, 1055, 10.1002/bjs.4297 · DOI
- Thun, 2002, Non-steroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues, J Natl Cancer Inst, 94, 252, 10.1093/jnci/94.4.252 · DOI · Paper page
- Therrasse, 2000, New guidelines toevaluate the response to treatment in solid tumors, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 · DOI · Paper page
- Blanke, 2002, A phase II trial of celecoxib, irinotecan, 5-fluorourail, and leucovorin in patients with unresectable or metastatic colorectal cancer: Proc, Am Soc Clin Oncol, 505, 21
- Saltz, 2000, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group, N Engl J Med, 343, 905, 10.1056/NEJM200009283431302 · DOI · Paper page
- Pan, 2003, A phase II trial of irinotecan, 5-fluorouracil, leucovorin (IFL), celecoxib and glutamine as first line therapy for advanced colorectal cancer: A Hoosier Oncology Group study, Proc Am Soc Clin Oncol, 1347, 22
- Lin, 2002, Ayers GD. effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity, Oncology, 16, 31
- Becerra, 2003, Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer. A phase II study, Int J Cancer, 105, 868, 10.1002/ijc.11164 · DOI
- Gasparini, 2005, Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer, The Oncologist, 10, 710, 10.1634/theoncologist.10-9-710 · DOI
- Maiello, 2000, 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomized phase II study of the Southern Italy Oncology group, Ann Oncol, 11, 1045, 10.1023/A:1008342928408 · DOI
- Solomon, 2005, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention, N Engl Med J, 353, 1071, 10.1056/NEJMoa050405 · DOI · Paper page
Cited by
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
Ruiz-Saenz, A., Atreya, C. E., Wang, C., Pan, B., Dreyer, C. A., Brunen, D., Prahallad, A., Muñoz, D. P., Ramms, D. J., Burghi, V., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00508-5 · Cited by 39
“Although several prior clinical trials testing SRC or COX2 inhibitors in patients with CRC have failed to show meaningful clinical activity 48–53 , no trial has yet focused on BRAF V600E mCRC or evaluated these agents in combination with BRAF-targeted therapies.”
Benjamin, D. J., Haslam, A., & Prasad, V. (2024) · Cancer Medicine · doi:10.1002/cam4.7049 · Cited by 30
Metadata
- Authors
- Maiello, E., Giuliani, F., Gebbia, V., Di Renzo, N., Pezzella, G., Romito, S., Mallamaci, R., Lopez, M., & Colucci, G.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2006-06
- Volume
- 17
- Pages
- vii55-vii59
- ISSN
- 0923-7534
- Cited by
- 25
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4942 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). https://app.cochat.ai/papers/10.1093/annonc/mdl952
- The paper
- Maiello, E., Giuliani, F., Gebbia, V., Di Renzo, N., Pezzella, G., Romito, S., Mallamaci, R., Lopez, M., & Colucci, G. (2006). FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology. https://doi.org/10.1093/annonc/mdl952
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.